NHS England Pauses New Prescriptions of Cross-Sex Hormones for Under-18s

NHS England has announced a pause on new prescriptions of cross-sex hormones for patients under the age of 18. The decision comes after an extensive review of clinical evidence regarding gender-related medical treatments for minors.

Policy Change Announced

According to health officials, the pause will apply to new patients seeking hormone treatments through NHS services. The move is part of an effort to ensure that medical treatments for young people are supported by strong clinical evidence and long-term safety data.

Existing patients who are already receiving treatment will continue to be monitored and supported under current medical guidelines.

Review of Clinical Evidence

The policy follows ongoing discussions among healthcare professionals and researchers about the effectiveness and potential risks associated with hormone therapy for adolescents.

Experts involved in the review emphasized the importance of careful medical assessment, psychological support, and comprehensive research before providing such treatments to minors.

Focus on Specialist Care

NHS England has indicated that future treatments for gender-related care will likely be handled through specialized research programs and expert clinical teams. The aim is to ensure that young patients receive care that is both safe and supported by strong scientific evidence.

Healthcare providers will also continue to offer mental health and counseling services to young people experiencing gender-related distress.

Public and Medical Response

The decision has sparked widespread discussion among medical professionals, advocacy groups, and policymakers. Some experts have welcomed the move as a precautionary step, while others have raised concerns about access to treatment for young people.

NHS England stated that the policy may be revisited in the future as more research and clinical data become available.